OUR PIPELINE

C. difficile most frequently affects older adults in hospitals or in long-term care facilities and typically occurs after the use of antibiotics.

C. difficile infections are increasing in incidence and severity and becoming more difficult to treat. The frequency of recurrent C. difficile infections also rising.

The CDC (Center for Disease Control) reported 223,900 C. diff. cases 2017 in the US and 12,800 deaths; the ECDC (European Centre for Disease Prevention and Control) estimated 124,000 C. diff. cases 2017 in the EU.

Sequestering iron is not only expected to inhibit C. diff. proliferation but it should also reduce toxin production and shift the GI microbiome towards healthier organisms.

DIBI will be eligible for the benefits of the QIDP (Qualified Infectious Disease Product) program C. diff.

QIDP includes fast track designation, priority review designation, and 5 years of additional market exclusivity.